http://orcid.org/0000-0001-8217-8950
Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hélène Babey, Gilles Quéré, Renaud Descourt, Ronan Le Calloch, Luca Lanfranco, Jean-Baptiste Nousbaum, Divi Cornec, Alice Tison & Christos Chouaid. (2018) Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. Expert Review of Anticancer Therapy 18:10, pages 981-989.
Read now
Read now
Abdul Rafeh Naqash, Li V. Yang, Edward J. Sanderlin, Druid C. Atwell & Paul R. Walker. (2018) Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncologica 57:5, pages 705-708.
Read now
Read now
Articles from other publishers (53)
Ping’an Ding, Pengpeng Liu, Lingjiao Meng & Qun Zhao. (2023) Mechanisms and biomarkers of immune-related adverse events in gastric cancer. European Journal of Medical Research 28:1.
Crossref
Crossref
Mick J.M. van Eijs, José J.M. ter Linde, Matthijs J.D. Baars, Mojtaba Amini, Miangela M. Laclé, Eelco C. Brand, Eveline M. Delemarre, Julia Drylewicz, Stefan Nierkens, Rik J. Verheijden, Bas Oldenburg, Yvonne Vercoulen, Karijn P.M. Suijkerbuijk & Femke van Wijk. (2023) Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis. iScience 26:10, pages 107891.
Crossref
Crossref
Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro & Alessandro Armuzzi. (2023) Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. International Journal of Molecular Sciences 24:14, pages 11504.
Crossref
Crossref
Anusha Shirwaikar Thomas, Stephen Hanauer & Yinghong Wang. (2023) Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 21:4, pages 878-890.
Crossref
Crossref
Yifan Zhou, Yusra B. Medik, Bhakti Patel, Daniel B. Zamler, Sijie Chen, Thomas Chapman, Sarah Schneider, Elizabeth M. Park, Rachel L. Babcock, Taylor T. Chrisikos, Laura M. Kahn, Allison M. Dyevoich, Josue E. Pineda, Matthew C. Wong, Aditya K. Mishra, Samuel H. Cass, Alexandria P. Cogdill, Daniel H. Johnson, Sarah B. Johnson, Khalida Wani, Debora A. Ledesma, Courtney W. Hudgens, Jingjing Wang, Md Abdul Wadud Khan, Christine B. Peterson, Aron Y. Joon, Weiyi Peng, Haiyan S. Li, Reetakshi Arora, Ximing Tang, Maria Gabriela Raso, Xuegong Zhang, Wai Chin Foo, Michael T. Tetzlaff, Gretchen E. Diehl, Karen Clise-Dwyer, Elizabeth M. Whitley, Matthew M. Gubin, James P. Allison, Patrick Hwu, Nadim J. Ajami, Adi Diab, Jennifer A. Wargo & Stephanie S. Watowich. (2023) Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. Journal of Experimental Medicine 220:2.
Crossref
Crossref
Kristian C. Williams, Abigail Gault, Amy E. Anderson, Christopher J. Stewart, Christopher A. Lamb, R. Ally Speight, Neil Rajan, Ruth Plummer & Arthur G. Pratt. (2023) Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. Frontiers in Immunology 14.
Crossref
Crossref
Vinayak Adimule, Basappa C Yallur & Sheetal Batakurki. 2023. Recent Developments in the Synthesis and Applications of Pyridines. Recent Developments in the Synthesis and Applications of Pyridines
127
143
.
Polaczek Mateusz Marek & Rutkowski Piotr. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
18
.
Marianne Gazzano, Christophe Parizot, Dimitri Psimaras, Aurore Vozy, Marine Baron, Baptiste Abbar, Vincent Fallet, Elena Litvinova, Anthony Canellas, Cristina Birzu, Valérie Pourcher, Mehdi Touat, Nicolas Weiss, Sophie Demeret, Damien Roos-Weil, Jean-Philippe Spano, Celeste Lebbe, Joe-Elie Salem, Jacques Cadranel, Baptiste Hervier, Guy Gorochov & Amélie Guihot. (2022) Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells. Frontiers in Immunology 13.
Crossref
Crossref
Dorte Lisbet Nielsen, Carsten Bogh Juhl, Inna Markovna Chen, Lauge Kellermann & Ole Haagen Nielsen. (2022) Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treatment Reviews 109, pages 102440.
Crossref
Crossref
Yingying Yu, Siyu Wang, Nan Su, Shida Pan, Bo Tu, Jinfang Zhao, Yingjuan Shen, Qin Qiu, Xiaomeng Liu, Junqing Luan, Fu-Sheng Wang, Fanping Meng & Ming Shi. (2022) Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Naoimh Herlihy & Roger Feakins. (2022) Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?. United European Gastroenterology Journal 10:5, pages 451-464.
Crossref
Crossref
Yared Hailemichael, Daniel H. Johnson, Noha Abdel-Wahab, Wai Chin Foo, Salah-Eddine Bentebibel, May Daher, Cara Haymaker, Khalida Wani, Chantal Saberian, Dai Ogata, Sang T. Kim, Roza Nurieva, Alexander J. Lazar, Hamzah Abu-Sbeih, Faisal Fa'ak, Antony Mathew, Yinghong Wang, Adewunmi Falohun, Van Trinh, Chrystia Zobniw, Christine Spillson, Jared K. Burks, Muhammad Awiwi, Khaled Elsayes, Luisa Solis Soto, Brenda D. Melendez, Michael A. Davies, Jennifer Wargo, Jonathan Curry, Cassian Yee, Gregory Lizee, Shalini Singh, Padmanee Sharma, James P. Allison, Patrick Hwu, Suhendan Ekmekcioglu & Adi Diab. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40:5, pages 509-523.e6.
Crossref
Crossref
Naoko Okiyama & Ryota Tanaka. (2022) Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergology International 71:2, pages 169-178.
Crossref
Crossref
Mungyo Jung, Mikyung Kang, Byung‐Seok Kim, Jihye Hong, Cheesue Kim, Choong‐Hyun Koh, Garam Choi, Yeonseok Chung & Byung‐Soo Kim. (2022) Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects. Advanced Materials 34:9, pages 2106516.
Crossref
Crossref
Mohammad Hossein Haddadi & Babak Negahdari. (2022) Clinical and diagnostic potential of regulatory T cell markers: From bench to bedside. Transplant Immunology 70, pages 101518.
Crossref
Crossref
Liansha Tang, Jialing Wang, Nan Lin, Yuwen Zhou, Wenbo He, Jiyan Liu & Xuelei Ma. (2021) Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. Frontiers in Immunology 12.
Crossref
Crossref
Stratigoula Sakellariou, Dionysia N. Zouki, Dimitrios C. Ziogas, Despoina Pouloudi, Helen Gogas & Ioanna Delladetsima. (2021) Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. BMC Gastroenterology 21:1.
Crossref
Crossref
Giorgos Bamias & Fabio Cominelli. (2021) Exploring the Early Phase of Crohn’s Disease. Clinical Gastroenterology and Hepatology 19:12, pages 2469-2480.
Crossref
Crossref
Harm Westdorp, Mark W. D. Sweep, Mark A. J. Gorris, Frank Hoentjen, Marye J. Boers-Sonderen, Rachel S. van der Post, Michel M. van den Heuvel, Berber Piet, Annemarie Boleij, Haiko J. Bloemendal & I. Jolanda M. de Vries. (2021) Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Frontiers in Immunology 12.
Crossref
Crossref
Sarah C. Sasson, Stephanie M. Slevin, Vincent T.F. Cheung, Isar Nassiri, Anna Olsson-Brown, Eve Fryer, Ricardo C. Ferreira, Dominik Trzupek, Tarun Gupta, Lulia Al-Hillawi, Mari-lenna Issaias, Alistair Easton, Leticia Campo, Michael E.B. FitzPatrick, Joss Adams, Meenali Chitnis, Andrew Protheroe, Mark Tuthill, Nicholas Coupe, Alison Simmons, Miranda Payne, Mark R. Middleton, Simon P.L. Travis, Benjamin P. Fairfax, Paul Klenerman & Oliver Brain. (2021) Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis. Gastroenterology 161:4, pages 1229-1244.e9.
Crossref
Crossref
V. P. Novikova, A. I. Khavkin & N. E. Prokopyeva. (2021) IBD-like gastrointestinal disorders in children. Experimental and Clinical Gastroenterology:4, pages 161-169.
Crossref
Crossref
Ying-Chun Lo, Christina Price, Kim Blenman, Pallavi Patil, Xuchen Zhang & Marie E Robert. (2021) Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal of Clinical Pathology 156:2, pages 214-228.
Crossref
Crossref
Marc A. Judson. (2021) A Primer on the Clinical Aspects of Sarcoidosis for the Basic and Translational Scientist. Journal of Clinical Medicine 10:13, pages 2857.
Crossref
Crossref
Ana Luisa Perdigoto, Harriet Kluger & Kevan C Herold. (2021) Adverse events induced by immune checkpoint inhibitors. Current Opinion in Immunology 69, pages 29-38.
Crossref
Crossref
Maria K. Magnusson, Alexander Vidal, Lujain Maasfeh, Stefan Isaksson, Rajneesh Malhotra, Henric K. Olsson & Lena Öhman. (2021) Impaired Butyrate Induced Regulation of T Cell Surface Expression of CTLA-4 in Patients with Ulcerative Colitis. International Journal of Molecular Sciences 22:6, pages 3084.
Crossref
Crossref
Jongdae Lee, Beatriz Lozano-Ruiz, Fengyuan Mandy Yang, Dengxia Denise Fan, Liya Shen & Jose M. González-Navajas. (2021) The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy. Frontiers in Immunology 12.
Crossref
Crossref
Josefien W. Hommes, Rik J. Verheijden, Karijn P. M. Suijkerbuijk & Dörte Hamann. (2021) Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review. Frontiers in Oncology 10.
Crossref
Crossref
Lillian Sun, Joshua Arbesman & Melissa Piliang. (2020) Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. Archives of Dermatological Research 313:1, pages 1-10.
Crossref
Crossref
S C Sasson, J J Zaunders, K Nahar, C M L Munier, B P Fairfax, A Olsson-Brown, C Jolly, S A Read, G Ahlenstiel, U Palendira, R A Scolyer, M S Carlino, M J Payne, V T F Cheung, T Gupta, P Klenerman, G V Long, O Brain, A M Menzies & A D Kelleher. (2020) Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. Clinical and Experimental Immunology 202:3, pages 335-352.
Crossref
Crossref
Hajir Ibraheim, Samantha Baillie, Mark A. Samaan, Hamzah Abu-Sbeih, Yinghong Wang, Nicholas J. Talley, Michael P. Jones & Nick Powell. (2020) Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Alimentary Pharmacology & Therapeutics 52:9, pages 1432-1452.
Crossref
Crossref
Bingnan Liu, Yuanyuan Shao, Xiaowei Liang, Dan Lu, Li Yan, Alexey Churov & Rong Fu. (2020) CTLA‐4 and HLA‐DQ are key molecules in the regulation of mDC‐mediated cellular immunity by Tregs in severe aplastic anemia. Journal of Clinical Laboratory Analysis 34:10.
Crossref
Crossref
Yezaz A Ghouri, Veysel Tahan & Bo Shen. (2020) Secondary causes of inflammatory bowel diseases. World Journal of Gastroenterology 26:28, pages 3998-4017.
Crossref
Crossref
Lina IrshaidMarie E. RobertXuchen Zhang. (2020) Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Archives of Pathology & Laboratory Medicine.
Crossref
Crossref
Seiichi Yano, Kenji Ashida, Ryuichi Sakamoto, Chihiro Sakaguchi, Masatoshi Ogata, Kengo Maruyama, Shohei Sakamoto, Munehiko Ikeda, Kenji Ohe, Shoko Akasu, Shimpei Iwata, Nobuhiko Wada, Yayoi Matsuda, Yoichi Nakanishi, Masatoshi Nomura & Yoshihiro Ogawa. (2020) Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency. European Journal of Cancer 130, pages 198-203.
Crossref
Crossref
Yue Li, Xiaohui Kang, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Li Zhang, Xiaowei Liu, Jiaming Qian & Li Zhang. (2020) Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system. Thoracic Cancer 11:4, pages 829-834.
Crossref
Crossref
Arezoo Hosseini, Tohid Gharibi, Faroogh Marofi, Zohreh Babaloo & Behzad Baradaran. (2020) CTLA-4: From mechanism to autoimmune therapy. International Immunopharmacology 80, pages 106221.
Crossref
Crossref
Anna Pavlick & Jeffrey Weber. 2020. Cutaneous Melanoma. Cutaneous Melanoma
1187
1214
.
Hajir Ibraheim, Esperanza Perucha & Nick Powell. (2019) Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology 58:Supplement_7, pages vii17-vii28.
Crossref
Crossref
Jocelyn R. Farmer. (2019) Testing Immune-Related Adverse Events in Cancer Immunotherapy. Clinics in Laboratory Medicine 39:4, pages 669-683.
Crossref
Crossref
Amir-Reza Abolhassani, Gerold Schuler, Michael Constantin Kirchberger & Lucie Heinzerling. (2019) C-reactive protein as an early marker of immune-related adverse events. Journal of Cancer Research and Clinical Oncology 145:10, pages 2625-2631.
Crossref
Crossref
Caoilfhionn Connolly, Kalindi Bambhania & Jarushka Naidoo. (2019) Immune-Related Adverse Events: A Case-Based Approach. Frontiers in Oncology 9.
Crossref
Crossref
J. Daniel Herlihy, Stephen Beasley, Andrew Simmelink, Vinaya Maddukuri, Asim Amin, Michal Kamionek, Carl Jacobs, Krista Bossi & Martin Scobey. (2019) Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis. Southern Medical Journal 112:3, pages 154-158.
Crossref
Crossref
Anna Pavlick & Jeffrey Weber. 2019. Cutaneous Melanoma. Cutaneous Melanoma
1
28
.
Emilie Soularue, Patricia Lepage, Jean Frederic Colombel, Clelia Coutzac, David Faleck, Lysiane Marthey, Michael Collins, Nathalie Chaput, Caroline Robert & Franck Carbonnel. (2018) Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 67:11, pages 2056-2067.
Crossref
Crossref
Spyros I. Siakavellas & Giorgos Bamias. (2018) Checkpoint inhibitor colitis. Current Opinion in Gastroenterology 34:6, pages 377-383.
Crossref
Crossref
Tilda Passat, Yann Touchefeu, Nadine Gervois, Anne Jarry, Céline Bossard & Jaafar Bennouna. (2018) Mécanismes physiopathologiques des effets secondaires des immunothérapies par anticorps anti-CTLA-4, anti-PD-1 et anti-PD-L1 dans le traitement du cancer. Bulletin du Cancer 105:11, pages 1033-1041.
Crossref
Crossref
David J.W. Paton, Lydia Warburton, Kim Chung, Tarek M. Meniawy & M. Priyanthi Kumarasinghe. (2018) Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of ‘immunomodulatory’ enterocolitis. Pathology 50:4, pages 466-469.
Crossref
Crossref
Ronald Anderson & Bernardo L. Rapoport. (2018) Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. Frontiers in Oncology 8.
Crossref
Crossref
Kathleen Birley, Kerry Chester & John Anderson. (2018) Antibody based therapy for childhood solid cancers. Current Opinion in Chemical Engineering 19, pages 153-162.
Crossref
Crossref
Sarah E. Umetsu, Ian Brown, Cord Langner & Gregory Y. Lauwers. (2017) Autoimmune enteropathies. Virchows Archiv 472:1, pages 55-66.
Crossref
Crossref
. (2017) Ipilimumab. Reactions Weekly 1671:1, pages 243-243.
Crossref
Crossref
Yared Hailemichael, Daniel H. Johnson, Noha Abdel-Wahab, Wai Chin Foo, May Daher, Cara Haymaker, Khalida M. Wani, Chantal M. Saberian, Dai Ogata, Salah Eddine Bentebibel, Sang Taek Kim, Roza Nurieva, Alexander Lazar, Hamzah Abu-Sbeih, Yinghong Wang, Van Anh Trinh, Chrystia M. Zobniw, Christine A. Spillson, Jared K. Burks, Luisa Solis, Alejandro Francisco Cruz, Mario Luiz Marques-Piubelli, Wei Lu, Brenda Denisse Melendez, Michael A. Davies, Jennifer Wargo, Jonathan L. Curry, Gregory A. Lizee, Cassian Yee, Patrick Hwu, Suhendan Ekmekcioglu & Adi Diab. (2021) Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. SSRN Electronic Journal.
Crossref
Crossref